Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNP | P00491 | 10/20 | 0.64 |
| ▸ | HPRT1 | P00492 | 1/20 | 0.46 |
| ▸ | MTAP | Q13126 | 8/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8246938 | 1.00 | PNP (0.64) | PNPHPRT1MTAP | |
| SCHEMBL505709 | 1.00 | PNP (0.64) | PNPHPRT1MTAP | |
| Hydrochloric Acid SCHEMBL4830734 | 0.99 | PNP (0.63) | PNPHPRT1MTAP | |
| SCHEMBL7100238 | 0.87 | PNP (0.60) | PNPHPRT1MTAP | |
| SCHEMBL5606739 | 0.87 | PNP (0.60) | PNPHPRT1MTAP | |
| SCHEMBL506019 | 0.87 | PNP (0.60) | PNPHPRT1MTAP | |
| Hydrochloric Acid SCHEMBL4065724 | 0.86 | PNP (0.59) | PNPHPRT1MTAP | |
| SCHEMBL14156772 | 0.85 | PNP (0.58) | PNPMTAP | |
| SCHEMBL505864 | 0.83 | MTAP (0.60) | PNPHPRT1MTAP | |
| SCHEMBL505499 | 0.83 | HPRT1 (0.50) | PNPHPRT1MTAP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070149466-A1 | Methods and related compositions for treating or preventing obesity, insulin resistance disorders, and mitochondrial-associated disorders | SIRTRIS PHARMACEUTICALS, INC. | 2007-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070149466-A1 | Methods and related compositions for treating or preventing obesity, insulin resistance disorders, and mitochondrial-associated disorders | SIRT1, SIRT3, SIRT2 | PNP 2885/4885HPRT1 3637/4885MTAP 4093/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.